Sign in

NCT06322017Recruiting

Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation

Source: ClinicalTrials.gov · Last updated 29 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Therapeutic management of Atrial Fibrillation (AF) is based either on heart rate control or on rhythm control, a strategy which aims to maintain a normal heart rhythm. The benefit in terms of morbidity and mortality of a normal heart rhythm would, however, be largely offset by the frequent side effects of antiarrhythmic drugs which could even lead to an increase in mortality compared to rate control. This increase has particularly been suggested in people aged over 75. Since the emergence of catheter Pulmonary Vein Isolation (PVI), an effective alternative to antiarrhythmic drugs has become available. This technique makes it possible to isolate the foci triggering AF under local or general anesthesia with greater effectiveness than medications and very low risks. Records in the elderly do not seem to show a reduction in effectiveness or an increase in complications. However, in the absence of a dedicated randomized study, its use is strongly limited in the elderly where rate control (52% of people over 65 years old) and the use of antiarrhythmic drugs are largely favored due to the simplicity of implementation and the low cost of medications. However, an early rhythm control strategy seems to reduce cardiovascular events in relatively old individuals (average age 70 years). The use of PVI in first line could make it possible to further improve these results. The objective of the investigator is therefore to carry out the first randomized comparative study proposing to evaluate the impact of early PVI compared to usual treatment in patients aged 75 and over with AF.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
294 (estimated)
First submitted
8 Feb 2024
Start date
9 Apr 2024
Primary completion date
9 Apr 2030
Lead sponsor
Nantes University Hospital
NCT number
NCT06322017

What you commit to

  • Study type: Interventional
  • Planned participants: 294
  • From 9 Apr 2024 to the primary completion date, 9 Apr 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Indication of cardiac pacing or defibrillation at baseline.
  • History of valve replacement, atrial occlusion or exclusion.
  • History of AF ablation.
  • Stroke less than 6 months old.
  • Severe cognitive impairment noted in history.

Lab values

  • Significant heart disease (structural with alteration of LVEF \<35%, congenital heart disease, hypertrophic heart disease with wall of more than 15 mm, revascularized coronary syndrome less than 3 months old).
  • Chronic renal failure (CKD - eGFR \<30 µMol/L).

Other

  • Contraindication to anticoagulation or an invasive procedure.
  • Uncontrolled dysthyroidism.
  • Patient under curatorship, guardianship, safeguard of justice.
  • Life expectancy less than 24 months.
  • Participation in another therapeutic trial likely to impact the study evaluation criteria.
  • Lack of understanding of the study.

Who the study is looking for

  • Man or woman aged 75 and over.
  • Paroxysmal AF or early recurrent or persistent paroxysmal AF first diagnosed less than 12 months ago.
  • Patient who consented to participate in the study.
  • Patient affiliated to a social security system.

Age in the registry: 75 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Nantes University Hospital
Coordinator of this site? Confirm its status
NantesFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.